Cardiol Therapeutics Inc Dossier
Outlook & Key Dates
Estimates, guidance, catalysts, and upcoming events
Analyst Estimates Learn more →
5-Yr Fwd EPS Growth
79.4%projected annual EPS growth
Analyst Coverage
4analysts covering
FY EPS (est.)
-$0.26next fiscal year
Reporting Calendar
| Event | Expected Date |
|---|---|
| Q3 2026 Financial Results Release | 12 Nov 2026 |
Monitoring Framework
Key Performance Indicators
MAVERIC Phase III Patient Enrollment Progress Quarterly75.0Target: 100% (approximately 110 patients)
Cash and Cash Equivalents (CAD) Quarterly27.7MTarget: Sufficient to fund operations into Q4 2027
Quarterly Net Loss (CAD) Quarterly-10.8MTarget: Controlled operational cash burn
Watch Items
- MAVERIC Phase III Trial Enrollment CompletionTrigger: 100% patient recruitment achievedAction: Prepare for database lock and subsequent top-line data analysis for NDA submission.
- CRD-38 IND Application SubmissionTrigger: Filing of IND with the FDAAction: Initiate Phase I clinical development for subcutaneous formulation in heart failure.
- Cash Runway and Capital AllocationTrigger: Cash balance falling below 12 months of operating expensesAction: Evaluate strategic partnerships, licensing opportunities, or non-dilutive funding to extend runway beyond Q4 2027.
Research as of 19 Jun 2026